COVID-19 vaccine for young people aged 12 to 17: Moderna submits authorisation application to Swissmedic

Another indication extension under rolling review


COVID-19 Vaccine Moderna, which was authorised as protection against the new coronavirus at the beginning of 2021, has until now been authorised for use in persons aged 18 and over. The authorisation holder – Moderna Switzerland GmbH – submitted an application for extension of the authorisation to the age group of 12- to 17-year-olds. Swissmedic is reviewing the application in the rolling procedure.

Swissmedic, the Swiss Agency for Therapeutic Products, is reviewing the data submitted, including the results of a large ongoing clinical trial with young people aged 12 years and up. As soon as there is sufficient evidence that the safety, efficacy and quality of the COVID-19 vaccine in this age group are adequate, Swissmedic will swiftly decide on the indication extension.

Address for enquiries

Media Unit  

+41 58 462 02 76